|
|
Proc Natl Acad Sci U S A. 1996 April 16; 93(8): 3243–3247. | PMCID: PMC39590 |
The C-terminal region of human angiogenin has a dual role in enzymatic activity. N Russo, V Nobile, A Di Donato, J F Riordan, and B L Vallee Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Boston, MA 02115, USA. Abstract The ribonucleolytic activity of angiogenin (Ang) is essential to Ang's capacity to induce blood vessel formation. Previous x-ray diffraction and mutagenesis results have shown that the active site of the human protein is obstructed by Gln-117 and imply that the C-terminal region of Ang must undergo a conformational rearrangement to allow substrate binding and catalysis. As a first step toward structural characterization of this conformational change, additional site-directed mutagenesis and kinetic analysis have been used to examine the intramolecular interactions that stabilize the inactive conformation of the protein. Two residues of this region, Ile-119 and Phe-120, are found to make hydrophobic interactions with the remainder of the protein and thereby help to keep Gln-117 in its obstructive position. Furthermore, the suppression of activity by the intramolecular interactions of Ile-119 and Phe-120 is counterbalanced by an effect of the adjacent residues, Arg-121, Arg-122, and Pro-123 which do not appear to form contacts with the rest of the protein structure. They contribute to enzymatic activity, probably by constituting a peripheral subsite for binding polymeric substrates. The results reveal the nature of the conformational change in human Ang and assign a key role to the C-terminal region both in this process and, presumably, in the regulation of human Ang function. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985 Sep 24;24(20):5480–5486. [PubMed]
- King TV, Vallee BL. Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J Bone Joint Surg Br. 1991 Jul;73(4):587–590. [PubMed]
- Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986 Jun 17;25(12):3527–3532. [PubMed]
- Moenner M, Gusse M, Hatzi E, Badet J. The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem. 1994 Dec 1;226(2):483–490. [PubMed]
- Shapiro R, Strydom DJ, Olson KA, Vallee BL. Isolation of angiogenin from normal human plasma. Biochemistry. 1987 Aug 11;26(16):5141–5146. [PubMed]
- Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Amino acid sequence of human tumor derived angiogenin. Biochemistry. 1985 Sep 24;24(20):5486–5494. [PubMed]
- Rybak SM, Vallee BL. Base cleavage specificity of angiogenin with Saccharomyces cerevisiae and Escherichia coli 5S RNAs. Biochemistry. 1988 Apr 5;27(7):2288–2294. [PubMed]
- Harper JW, Vallee BL. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis. Biochemistry. 1989 Feb 21;28(4):1875–1884. [PubMed]
- Russo N, Shapiro R, Acharya KR, Riordan JF, Vallee BL. Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2920–2924. [PubMed]
- Shapiro R, Fox EA, Riordan JF. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry. 1989 Feb 21;28(4):1726–1732. [PubMed]
- Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 1989 Sep 5;28(18):7401–7408. [PubMed]
- Curran TP, Shapiro R, Riordan JF. Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis. Biochemistry. 1993 Mar 9;32(9):2307–2313. [PubMed]
- Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2915–2919. [PubMed]
- Acharya KR, Shapiro R, Riordan JF, Vallee BL. Crystal structure of bovine angiogenin at 1.5-A resolution. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2949–2953. [PubMed]
- Wlodawer A, Svensson LA, Sjölin L, Gilliland GL. Structure of phosphate-free ribonuclease A refined at 1.26 A. Biochemistry. 1988 Apr 19;27(8):2705–2717. [PubMed]
- Shapiro R, Vallee BL. Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry. 1992 Dec 15;31(49):12477–12485. [PubMed]
- Di Donato A, Cafaro V, de Nigris M, Rizzo M, D'Alessio G. The determinants of the dimeric structure of seminal ribonuclease are located in its N-terminal region. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1440–1445. [PubMed]
- Di Donato A, Cafaro V, D'Alessio G. Ribonuclease A can be transformed into a dimeric ribonuclease with antitumor activity. J Biol Chem. 1994 Jul 1;269(26):17394–17396. [PubMed]
- Shapiro R, Weremowicz S, Riordan JF, Vallee BL. Ribonucleolytic activity of angiogenin: essential histidine, lysine, and arginine residues. Proc Natl Acad Sci U S A. 1987 Dec;84(24):8783–8787. [PubMed]
- Shapiro R, Fett JW, Strydom DJ, Vallee BL. Isolation and characterization of a human colon carcinoma-secreted enzyme with pancreatic ribonuclease-like activity. Biochemistry. 1986 Nov 18;25(23):7255–7264. [PubMed]
- Curran TP, Shapiro R, Riordan JF. Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis. Biochemistry. 1993 Mar 9;32(9):2307–2313. [PubMed]
- Harper JW, Vallee BL. Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7139–7143. [PubMed]
- Bond MD, Strydom DJ, Vallee BL. Characterization and sequencing of rabbit, pig and mouse angiogenins: discernment of functionally important residues and regions. Biochim Biophys Acta. 1993 Mar 5;1162(1-2):177–186. [PubMed]
- Russo N, Acharya KR, Vallee BL, Shapiro R. A combined kinetic and modeling study of the catalytic center subsites of human angiogenin. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):804–808. [PubMed]
- Beintema JJ, Schüller C, Irie M, Carsana A. Molecular evolution of the ribonuclease superfamily. Prog Biophys Mol Biol. 1988;51(3):165–192. [PubMed]
- D'Alessio G. Oligomer evolution in action? Nat Struct Biol. 1995 Jan;2(1):11–13. [PubMed]
- Hallahan TW, Shapiro R, Vallee BL. Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2222–2226. [PubMed]
|